David Rosenbaum
Chief Development Officer Syntis Bio
David Rosenbaum recently joined Syntis Bio as the Chief Development Officer. In this role, he is responsible for overseeing the development of oral therapies that leverage the unique biology of the small intestine to address metabolic control, digestion, and drug absorption. His expertise is crucial in advancing the company’s clinical programs and bringing new therapies to patients.
Seminars
Thursday 16th July 2026
Replicating the Surgical “Gold Standard” by Utilizing a Synthetic TissueLining to Mimic Gastric Bypass via a Once-Daily Pill
10:00 am
- Utilizing a transient polydopamine polymer coating to precisely block nutrient absorption in the duodenum for 24 hours, providing a non-systemic “take-anytime” oral convenience that triggers the body’s natural satiety cascade (GLP-1 and PYY) without the gastrointestinal side effects of exogenous peptide hormones
- Matching the 1% weekly weight-loss efficacy observed in preclinical models while achieving 100% preservation of lean muscle mass, offering a potent oral alternative that solves the “muscle-wasting” crisis of current injectables and could capture significant market share among patients seeking “healthy” functional weight loss
- Optimizing the metabolic environment of the small intestine to ensure steady-state glycemic control and appetite suppression, bypassing the “peaks and troughs” of injectable delivery and establishing a sustainable, low-cost maintenance therapy that prevents the biological “rebound” of weight regain
